文献速递免疫规划传染病防控与疫情报告

年龄、族裔、性别及既往感染对单剂BNT162b2 mRNA新冠疫苗免疫原性的影响:以色列医护人员真实世界证据

Impact of age, ethnicity, sex and prior infection status on immunogenicity following a single dose of the BNT162b2 mRNA COVID-19 vaccine: real-world evidence from healthcare workers, Israel, December 2020 to January 2021.
PubMed 文献 · Euro Surveill · 2021-01-01

该研究在514名以色列医护人员中评估接种第一剂BNT162b2 mRNA新冠疫苗后21天的免疫原性,按年龄、族裔、性别和既往新冠感染状态分层。结果显示免疫原性在族裔和性别间相似,但随年龄增长而下降;既往感染者无论接种前是否可检测到IgG抗体,抗体滴度均比未感染者高一个数量级。

要点

  • 第一剂BNT162b2后21天免疫原性随年龄增长而下降。
  • 族裔和性别间免疫原性相似。
  • 既往感染者抗体滴度比未感染者高一个数量级。

核心结论

  • 单剂BNT162b2 mRNA疫苗接种后21天免疫原性随年龄增长而下降,既往新冠感染者抗体滴度显著高于未感染者。

研究设计与样本

  • 观察性研究,纳入514名以色列医护人员,评估接种第一剂BNT162b2 mRNA疫苗后21天的免疫原性。

主要发现

  • 免疫原性在族裔和性别间相似。
  • 免疫原性随年龄增长而下降。
  • 既往感染者抗体滴度比未感染者高一个数量级,无论接种前是否可检测到IgG抗体。

临床怎么用

  • 真实世界数据提示年龄和既往感染状态影响单剂BNT162b2疫苗的免疫应答,可为接种策略提供参考。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The BNT162b2 mRNA COVID-19 vaccine showed high efficacy in clinical trials but observational data from populations not included in trials are needed. We describe immunogenicity 21 days post-dose 1 among 514 Israeli healthcare workers by age, ethnicity, sex and prior COVID-19 infection. Immunogenicity was similar by ethnicity and sex but decreased with age. Those with prior infection had antibody titres one magnitude order higher than naïve individuals regardless of the presence of detectable IgG antibodies pre-vaccination.

来源:Euro Surveill,查看原文。版权归原作者所有。

引用

  1. Abu Jabal K, Ben-Amram H, Beiruti K, et al. Impact of age, ethnicity, sex and prior infection status on immunogenicity following a single dose of the BNT162b2 mRNA COVID-19 vaccine: real-world evidence from healthcare workers, Israel, December 2020 to January 2021. Euro Surveill. 2021. PMID: 33573712. doi:10.2807/1560-7917.ES.2021.26.6.2100096

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。